Skip to Content

Alirocumab Dosage

Applies to the following strengths: 75 mg/mL; 150 mg/mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Homozygous Familial Hypercholesterolemia

Initial dose: 75 mg subcutaneously every 2 weeks
Maximum dose: 150 mg subcutaneously every 2 weeks, if the LDL-C response to initial dose is inadequate

Comments: Measure LDL-C levels within 4 to 8 weeks of initiation or titration to assess response; adjust the dose, if needed.

Uses: Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C

Usual Adult Dose for Cardiovascular Risk Reduction

Initial dose: 75 mg subcutaneously every 2 weeks
Maximum dose: 150 mg subcutaneously every 2 weeks, if the LDL-C response to initial dose is inadequate

Comments: Measure LDL-C levels within 4 to 8 weeks of initiation or titration to assess response; adjust the dose, if needed.

Uses: Adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C

Renal Dose Adjustments

Mild to moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction: No data available

Liver Dose Adjustments

Mild to moderate hepatic dysfunction: No adjustment recommended.
Severe hepatic dysfunction: No data available

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Administer this drug by subcutaneous injection into the thigh, abdomen, or upper arm using a single-dose prefilled pen or single-dose prefilled syringe.
-Rotate the injection site.
-The injection should not be administered into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, or skin infections.
-This drug should not be co-administered with other injectable drugs at the same injection site.

Missed Dose:
-Administer the injection within 7 days from the missed dose and then resume the patient's original schedule.
-If the missed dose is not administered within 7 days, wait until the next dose on the original schedule.

Storage requirements: Store in the refrigerator between 36F to 46F (2C to 8C)

Reconstitution/preparation techniques:
-Allow this drug to warm to room temperature for 30 to 40 minutes prior to use; use this drug as soon as possible after it has warmed up. This drug should not be used if it has been at room temperature [77F (25C)] for 24 hours or longer.
-Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The solution should not be used if it is discolored or contains visible particulate matter.
-Follow aseptic injection techniques.
-Provide proper training to patients and/or caregivers on the preparation and administration of this drug prior to use. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use this drug.

Limitations of use:
-The effect of this drug on cardiovascular morbidity and mortality has not been determined.

Monitoring: LDL levels

Patient advice:
-If any signs or symptoms of serious allergic reactions occur, discontinue this drug and seek medical attention.
-Patients and caregivers should read the Patient Information and Instructions For Use (IFU) before starting this drug, and with each refill.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide